Measurement of Tamoxifen in Serum by Thin-layer Densitometry
Overview
Affiliations
A method is described for the determination of tamoxifen in serum. The drug was extracted from the serum and separated from its metabolites by thin-layer chromatography. Irradiation of the thin-layer plate with ultra-violet light after development converted tamoxifen to a fluorescent product which could be estimated in situ by densitometry. The fluorescent product was identified as a substituted phenanthrene by thin-layer chromatography, and gas chromatography--mass spectrometry. The method allowed concentrations as low as 6.8 nmol/l serum to be measured. After an oral dose of tamoxifen (10 mg) to a female patient the maximum serum concentration (66.2 nmol/l) was achieved in 3 h. When 10 mg tamoxifen were taken twice daily for 21 days by the same patient serum concentrations of about 500 nmol/l were achieved.
Jordan V Steroids. 2007; 72(13):829-42.
PMID: 17765940 PMC: 2740485. DOI: 10.1016/j.steroids.2007.07.009.
Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer.
Wilkinson P, Ribeiro G, Adam H, Patterson J Cancer Chemother Pharmacol. 1980; 5(2):109-11.
PMID: 7471314 DOI: 10.1007/BF00435413.
Wilkinson P, Ribiero G, Adam H, Kemp J, Patterson J Cancer Chemother Pharmacol. 1982; 10(1):33-5.
PMID: 7160042 DOI: 10.1007/BF00257234.
Jordan V Breast Cancer Res Treat. 1983; 3 Suppl:S73-86.
PMID: 6423014 DOI: 10.1007/BF01855131.
BRATHERTON D, Brown C, Buchanan R, Hall V, Kingsley Pillers E, Wheeler T Br J Cancer. 1984; 50(2):199-205.
PMID: 6380554 PMC: 1976875. DOI: 10.1038/bjc.1984.163.